The Plasma Contact System 2.0

ABSTRACT

The contact system is a protease cascade that is initiated by factor XII activation on cardiovascular cells. The system starts procoagulant and proinflammatory reactions, via the intrinsic pathway of coagulation and the kallikrein-kinin system, respectively. The biochemistry of the contact system in vitro is well understood. However, activators of the system in vivo and their contributions to disease states have remained enigmatic. Recent experimental and clinical data have identified misfolded proteins, collagens, and polyphosphates as the long-sought activators of the contact system in vivo. Here we present an overview about contact system activators and their contributions to health and pathology.

KEYWORDS

Factor XII - polyphosphates - misfolded proteins - collagen - kallikrein-kinin system

REFERENCES

• 1 Renné T, Dedio J, Meijers J C, Chung D, Müller-Esterl W. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2.  J Biol Chem. 1999;  274 (36) 25777-25784
• 2 Müller F, Renné T. Novel roles for factor XII-driven plasma contact activation system.  Curr Opin Hematol. 2008;  15 (5) 516-521
• 3 Revak S D, Cochrane C G, Bouma B N, Griffin J H. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma.  J Exp Med. 1978;  147 (3) 719-729
• 4 Renné T, Schuh K, Müller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans.  J Immunol. 2005;  175 (5) 3377-3385
• 5 Kluft C, Trumpi-Kalshoven M M, Jie A F, Veldhuyzen-Stolk E C. Factor XII-dependent fibrinolysis: a double function of plasma kallikrein and the occurrence of a previously undescribed factor XII- and kallikrein-dependent plasminogen proactivator.  Thromb Haemost. 1979;  41 (4) 756-773
• 6 Ghebrehiwet B, Silverberg M, Kaplan A P. Activation of the classical pathway of complement by Hageman factor fragment.  J Exp Med. 1981;  153 (3) 665-676
• 7 Renné T, Gailani D. Role of factor XII in hemostasis and thrombosis: clinical implications.  Expert Rev Cardiovasc Ther. 2007;  5 (4) 733-741
• 8 Gailani D, Broze Jr G J. Factor XI activation in a revised model of blood coagulation.  Science. 1991;  253 (5022) 909-912
• 9 Pedicord D L, Seiffert D, Blat Y. Feedback activation of factor XI by thrombin does not occur in plasma.  Proc Natl Acad Sci U S A. 2007;  104 (31) 12855-12860
• 10 Kravtsov D V, Matafonov A, Tucker E I et al.. Factor XI contributes to thrombin generation in the absence of factor XII.  Blood. 2009;  114 (2) 452-458
• 11 Maas C, Meijers J C, Marquart J A et al.. Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma.  Proc Natl Acad Sci U S A. 2010;  107 (20) 9083-9087
• 12 Schulze-Topphoff U, Prat A, Prozorovski T et al.. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system.  Nat Med. 2009;  15 (7) 788-793
• 13 Leeb-Lundberg L M, Marceau F, Müller-Esterl W, Pettibone D J, Zuraw B L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences.  Pharmacol Rev. 2005;  57 (1) 27-77
• 14 Renné T, Dedio J, David G, Müller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells.  J Biol Chem. 2000;  275 (43) 33688-33696
• 15 Stavrou E, Schmaier A H. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis.  Thromb Res. 2010;  125 (3) 210-215
• 16 Nielsen V G. Corn trypsin inhibitor decreases tissue-type plasminogen activator-mediated fibrinolysis of human plasma.  Blood Coagul Fibrinolysis. 2009;  20 (3) 191-196
• 17 Brown N J, Gainer J V, Stein C M, Vaughan D E. Bradykinin stimulates tissue plasminogen activator release in human vasculature.  Hypertension. 1999;  33 (6) 1431-1435
• 18 Levi M, Hack C E, de Boer J P, Brandjes D P, Büller H R, ten Cate J W. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo.  J Clin Invest. 1991;  88 (4) 1155-1160
• 19 Lund L R, Green K A, Stoop A A et al.. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.  EMBO J. 2006;  25 (12) 2686-2697
• 20 Lilla J N, Werb Z. Mast cells contribute to the stromal microenvironment in mammary gland branching morphogenesis.  Dev Biol. 2010;  337 (1) 124-133
• 21 Lilla J N, Joshi R V, Craik C S, Werb Z. Active plasma kallikrein localizes to mast cells and regulates epithelial cell apoptosis, adipocyte differentiation, and stromal remodeling during mammary gland involution.  J Biol Chem. 2009;  284 (20) 13792-13803
• 22 Ratnoff O D, Colopy J E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma.  J Clin Invest. 1955;  34 (4) 602-613
• 23 Ratnoff O D, Busse Jr R J, Sheon R P. The demise of John Hageman.  N Engl J Med. 1968;  279 (14) 760-761
• 24 Cushman M, O'Meara E S, Folsom A R, Heckbert S R. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology.  Blood. 2009;  114 (14) 2878-2883
• 25 Müller F, Mutch N J, Schenk W A et al.. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.  Cell. 2009;  139 (6) 1143-1156
• 26 Hathaway W E, Wuepper K D, Weston W L et al.. Clinical and physiologic studies of two siblings with prekallikrein (Fletcher factor) deficiency.  Am J Med. 1976;  60 (5) 654-664
• 27 Pavletic A. Angioedema of the intestine.  N Engl J Med. 1996;  335 (20) 1534 author reply 1535
• 28 Cichon S, Martin L, Hennies H C et al.. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III.  Am J Hum Genet. 2006;  79 (6) 1098-1104
• 29 Nielsen E W, Johansen H T, Høgåsen K, Wuillemin W, Hack C E, Mollnes T E. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema.  Scand J Immunol. 1996;  44 (2) 185-192
• 30 Lehmann A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery.  Expert Opin Biol Ther. 2008;  8 (8) 1187-1199
• 31 Marqués L, Domingo D, Maravall F J, Clotet J. Short-term prophylactic treatment of hereditary angioedema with icatibant.  Allergy. 2010;  65 (1) 137-138
• 32 Wright F L, Hua H T, Velmahos G, Thoman D, Demitriades D, Rhee P M. Intracorporeal use of the hemostatic agent QuickClot in a coagulopathic patient with combined thoracoabdominal penetrating trauma.  J Trauma. 2004;  56 (1) 205-208
• 33 Kheirabadi B S, Mace J E, Terrazas I B et al.. Safety evaluation of new hemostatic agents, smectite granules, and kaolin-coated gauze in a vascular injury wound model in swine.  J Trauma. 2010;  68 (2) 269-278
• 34 Devlin J J, Kircher S, Kozen B G, Littlejohn L F, Johnson A S. Comparison of ChitoFlex(R), CELOX, and QuikClot(R) in Control of Hemorrhage.  J Emerg Med. 2009; April 1;  (Epub ahead of print)
• 35 Samuel M, Pixley R A, Villanueva M A, Colman R W, Villanueva G B. Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies.  J Biol Chem. 1992;  267 (27) 19691-19697
• 36 Siebeck M, Cheronis J C, Fink E et al.. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors.  J Appl Physiol. 1994;  77 (6) 2675-2680
• 37 Kishimoto T K, Viswanathan K, Ganguly T et al.. Contaminated heparin associated with adverse clinical events and activation of the contact system.  N Engl J Med. 2008;  358 (23) 2457-2467
• 38 Hojima Y, Cochrane C G, Wiggins R C, Austen K F, Stevens R L. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E.  Blood. 1984;  63 (6) 1453-1459
• 39 Ratnoff O D, Saito H. The evolution of clot-promoting and amidolytic activities in mixtures of Hageman factor (factor XII) and ellagic acid.  J Lab Clin Med. 1982;  100 (2) 248-260
• 40 Girolami A, Cliffton E E. Hypercoagulable state induced in humans by the intravenous administration of purified ellagic acid.  Thromb Diath Haemorrh. 1967;  17 (1–2) 165-175
• 41 Iatridis S G, Iatridis P G, Ferguson J H. Effects of ellagic acid upon the human fibrinolytic system.  Thromb Diath Haemorrh. 1966;  16 (3) 656-667
• 42 Bhargava U C, Westfall B A. The mechanism of blood pressure depression by ellagic acid.  Proc Soc Exp Biol Med. 1969;  132 (2) 754-756
• 43 Kleinschnitz C, Stoll G, Bendszus M et al.. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis.  J Exp Med. 2006;  203 (3) 513-518
• 44 Merkulov S, Zhang W M, Komar A A et al.. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis.  Blood. 2008;  111 (3) 1274-1281
• 45 Renné T, Pozgajová M, Grüner S et al.. Defective thrombus formation in mice lacking coagulation factor XII.  J Exp Med. 2005;  202 (2) 271-281
• 46 Gailani D, Renné T. Intrinsic pathway of coagulation and arterial thrombosis.  Arterioscler Thromb Vasc Biol. 2007;  27 (12) 2507-2513
• 47 Gailani D, Renné T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease?.  J Thromb Haemost. 2007;  5 (6) 1106-1112
• 48 Gebbink M F, Bouma B, Maas C, Bouma B N. Physiological responses to protein aggregates: fibrinolysis, coagulation and inflammation (new roles for old factors).  FEBS Lett. 2009;  583 (16) 2691-2699
• 49 Bergamaschini L, Donarini C, Gobbo G, Parnetti L, Gallai V. Activation of complement and contact system in Alzheimer's disease.  Mech Ageing Dev. 2001;  122 (16) 1971-1983
• 50 Bergamaschini L, Canziani S, Bottasso B, Cugno M, Braidotti P, Agostoni A. Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.  Clin Exp Immunol. 1999;  115 (3) 526-533
• 51 Maas C, Govers-Riemslag J W, Bouma B et al.. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.  J Clin Invest. 2008;  118 (9) 3208-3218
• 52 Bouma B, Maas C, Hazenberg B P, Lokhorst H M, Gebbink M F. Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses.  J Thromb Haemost. 2007;  5 (6) 1139-1142
• 53 Schmaier A H. The elusive physiologic role of factor XII.  J Clin Invest. 2008;  118 (9) 3006-3009
• 54 Herwald H, Renné T, Meijers J C et al.. Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4.  J Biol Chem. 1996;  271 (22) 13061-13067
• 55 Renné T, Gailani D, Meijers J C, Müller-Esterl W. Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein.  J Biol Chem. 2002;  277 (7) 4892-4899
• 56 Citarella F, Ravon D M, Pascucci B, Felici A, Fantoni A, Hack C E. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces.  Eur J Biochem. 1996;  238 (1) 240-249
• 57 Citarella F, te Velthuis H, Helmer-Citterich M, Hack C E. Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII—an immunochemical and homology modeling approach.  Thromb Haemost. 2000;  84 (6) 1057-1065
• 58 Maas C, Schiks B, Strangi R D et al.. Identification of fibronectin type I domains as amyloid-binding modules on tissue-type plasminogen activator and three homologs.  Amyloid. 2008;  15 (3) 166-180
• 59 Wilner G D, Nossel H L, LeRoy E C. Activation of Hageman factor by collagen.  J Clin Invest. 1968;  47 (12) 2608-2615
• 60 van der Meijden P E, Munnix I C, Auger J M et al.. Dual role of collagen in factor XII-dependent thrombus formation.  Blood. 2009;  114 (4) 881-890
• 61 Reininger A J, Bernlochner I, Penz S M et al.. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques.  J Am Coll Cardiol. 2010;  55 (11) 1147-1158
• 62 Mao Y, Getz T M, Jin J, Kunapuli S P. Coagulation factor XIIa activates platelets and is the physiological agonist of protease-activated receptor 3.  Blood. 2009;  114 770A
• 63 Castaldi P A, Larrieu M J, Caen J. Availability of platelet factor 3 and activation of factor XII in thrombasthenia.  Nature. 1965;  207 (995) 422-424
• 64 Johne J, Blume C, Benz P M et al.. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma.  Biol Chem. 2006;  387 (2) 173-178
• 65 Bäck J, Sanchez J, Elgue G, Ekdahl K N, Nilsson B. Activated human platelets induce factor XIIa-mediated contact activation.  Biochem Biophys Res Commun. 2010;  391 (1) 11-17
• 66 Ruiz F A, Lea C R, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes.  J Biol Chem. 2004;  279 (43) 44250-44257
• 67 Smith S A, Mutch N J, Baskar D, Rohloff P, Docampo R, Morrissey J H. Polyphosphate modulates blood coagulation and fibrinolysis.  Proc Natl Acad Sci U S A. 2006;  103 (4) 903-908
• 68 Smith S A, Morrissey J H. Polyphosphate as a general procoagulant agent.  J Thromb Haemost. 2008;  6 (10) 1750-1756